Introduction {#Sec1}
============

Pathology from excess ectopic bone formation following musculoskeletal injury, or trauma-induced heterotopic ossification (HO), presents a substantial barrier to recovery in 20% of patients with hip replacements, musculoskeletal trauma, neurologic injury, and blast/burn injuries.^[@CR1],[@CR2]^ Patients with HO experience substantive morbidity including chronic pain, restricted joint function, and open wounds. Effective therapeutics are lacking in contemporary medicine aside from surgical excision. However, these procedures can fail to completely reverse the joint contractures and restricted range of motion.^[@CR3]^ Furthermore, even after a successful excision procedure, recurrence may occur via similar cellular mechanisms as observed in HO from the incident trauma.^[@CR4]--[@CR6]^

While the etiologies of HO are diverse, it often follows a predictable progression of endochondral ossification^[@CR7]--[@CR10]^ after acute inflammatory insult with proliferation of progenitor populations of multipotent mesenchymal stromal cells (MSCs),^[@CR11]--[@CR13]^ chondrogenesis, angiogenesis, and ossification^[@CR7]^ resulting in highly vascular regions surrounding the HO.^[@CR14]^ These observations parallel programming seen in normal developing bone and fracture healing, suggesting overlapping pathways between developing bone and posttraumatic HO such as the intimate coupling of vascular invasion and osteogenesis.^[@CR15]^ Previous studies have further demonstrated MSCs differentiating into a cartilaginous scaffold and supportive matrix,^[@CR16]^ forming a hypoxic environment responsible for the upregulation of HIF1a and VEGFA.^[@CR17]--[@CR19]^ During normal bone formation, VEGFA facilitates co-invasion of this anlagen by neovasculature and Osterix(Osx)-expressing osteoblast precursors,^[@CR16]^ with increased delivery of oxygen to support growing metabolic activity.^[@CR20]^ Similar migratory behavior to primary ossification centers by osteoblast precursors was observed in response to VEGFA secreted by chondrocytes.^[@CR21]^ Disruption of these processes lead to impaired endochondral ossification.^[@CR8],[@CR22]^ Notably, mice with conditional deletion of VEGFA in *Col2a* expressing cells demonstrate aberrations in cartilage development and increased chondrocyte apoptosis.^[@CR13],[@CR23]^ The role of VEGFA as a pro-angiogenic/osteogenic signal^[@CR24]--[@CR26]^ fundamental to bone development and homeostasis^[@CR27]^ highlights a promising candidate for uncoupling acute injury and ectopic bone formation. Though previous studies have demonstrated the role of endothelial progenitors and VEGFA^[@CR28]^ in bone development and in a nontraumatic HO model, previous work did not identify the role of mesenchymal-derived VEGFA in traumatic HO.

Acute posttraumatic inflammation stimulates local^[@CR13],[@CR29]^ and recruited MSCs to secrete a collection of soluble factors^[@CR30],[@CR31]^ including VEGFA.^[@CR32]^ However, MSCs have been well demonstrated to be a heterogeneous population^[@CR13]^ and thus the true lineage and source of these progenitor cells have remained unclear. Various origins have been proposed for the progenitor cells responsible for HO including Tie2/vWF/VeCadherin-positive endothelium,^[@CR33]^ Prx1/Mx-1/PDGFRα-positive muscle interstitial fibro-adipogenic progenitors,^[@CR34]--[@CR36]^ scleraxis (Scx) lineage tendon derived stem cells^[@CR37]^ and a myriad of other identifying markers.^[@CR13],[@CR38]--[@CR41]^ Further illustrating the vast heterogeneity of involved cell lineages, additional peripheral progenitor niches such as those marked by odd-skipped related (Osr1, Osr2) genes^[@CR42]^ and engrailed1 (En1)^[@CR43]^ may also be involved although not yet implicated with HO.

Given the role of VEGFA during normal bone development and the infiltration of mesenchymal stem cells throughout the formation of HO, we hypothesized that interruption of progenitor-cell-derived VEGFA would lead to a reduction in posttraumatic HO formation. We demonstrate that mesenchymal progenitors are a significant source of VEGFA important for ectopic bone formation and cell-specific inhibition of this signal significantly reduces posttraumatic HO.

Results {#Sec2}
=======

Extremity trauma and inflammation induces a pro-angiogenic environment characterized by an increase in total endothelial structures {#Sec3}
-----------------------------------------------------------------------------------------------------------------------------------

Previous studies have demonstrated the upregulation of vascular signaling prior to pre-HO chondrogenesis.^[@CR28]^ However, high-resolution imaging of the actual vessels have not been obtained in relation to HO after trauma. To do this, we performed multiple modalities to corroborate the increase in vascular density at multiple timepoints across the progression of endochondral ossification, including the acute phase after injury (20 h) and plateau of ossification (9 weeks). First, we used near infrared in vivo interrogation using Angiosense 750EX to image the mouse hindlimb and demonstrate a robust increase in blood flow (Fig. [1a](#Fig1){ref-type="fig"}). Next, to obtain a high resolution and anatomic assessment of the vascular network implicated with HO formation, we performed microfil injection and nano-CT imaging. We visualized two distinct regions of increased vascular growth around the calcaneus in the distal hindlimb (Fig. [1b](#Fig1){ref-type="fig"}, red inset) and proximal to the tibial/fibular fuse point in the injured leg. HO formed in close proximity to corresponding vascular beds at 9 weeks (as demonstrated by microCT analyzed at density thresholds above the intravascular polymer) leading us to conclude that there was indeed involvement of vasculature following the peripheral injury with both increased blood flow and angiogenesis at the injury site. To further characterize the cell surface markers of the infiltrating cells at the HO site at more subacute timepoints, we performed flow cytometry of the injured tissue, specifically interrogating two specific cell types: potentially increasing endothelium per microfil imaging and a progenitor niche capable of undergoing transition to connective tissues^[@CR44]^ to contribute to the HO anlagen. FACS analysis of the injury site highlighted a significant enrichment of CD31^−^ Tie2^−^ CD34^+^ CD133^+\ [@CR45]--[@CR47]^ (Fig. [1c](#Fig1){ref-type="fig"}) endothelial progenitor cells (EPCs) in burn/tenotomy mice at 1 and 2 weeks (2.70 and 3.36-fold increases compared with uninjured contralateral leg, *P* = 0.032 and 0.002, respectively). There was not similar enrichment of mature endothelium at the 1 or 2 week timepoints (Fig. [1d](#Fig1){ref-type="fig"}). Given previous literature demonstrating the autocrine nature of VEGFA in vascular homeostasis,^[@CR48]^ this cellular enrichment of EPCs is consistent with a robust induction of neovasculature and also suggest these progenitor cells as a possible source for VEGFA signaling involved in the angiogenesis associated with HO development consistent with previously described nontrauma HO models.^[@CR28]^ Thus, we demonstrate using several different modalities that during HO formation, a rich, patent vascular network intimately surrounds the bone, is more prominent than in the uninjured extremity, and likely a facilitative influence in the progression of ectopic of endochondral ossification.Fig. 1Focal injury superimposed upon systemic inflammation induces robust local angiogenesis and produces enrichment of endothelial progenitors at the injury site. **a** Angiosense IVIS demonstrates increased perfusion to injured hindlimb at 20 h post surgery (representative images from *n* = 3 per group). **b** MICROFIL perfusion nano-CT images and micro-CT of mature mice show networks of nascent vessel outgrowth in regions of subsequent HO formation following burn tenotomy (green inset) at 9 weeks. Vessels in the distal hindlimb exhibit dense vascular infiltration (red inset). **c** FACS gating schema of injury site 2 weeks after burn tenotomy. CD31^−^ Tie2^−^ CD34^+^ CD133^+^ endothelial progenitor cells (EPC, blue) identified via R1 + R3. CD31^+^ Tie2^+^ CD34^−^ mature endothelial cells (red) identified via R2 + R4. Remaining live events were collected by surface marker depletion. **d** Proportion of gated EPC and mature endothelium from all live cells as assessed by flow cytometry was quantified at 1 week and 2 weeks post burn tenotomy

Vascular progenitors are not the contributing source for VEGFA at the burn/tenotomy injury site {#Sec4}
-----------------------------------------------------------------------------------------------

Given the enrichment of EPCs demonstrated by flow cytometry, we performed a directed single-cell RNA sequencing experiment in order to characterize transcriptome-level expression of *Vegfa* and the cellular subpopulations producing these transcripts at baseline preinjury (day 0), and days 3, 7, and 21 postinductive burn/tenotomy. Clustering analysis was performed by blinded biostatistician. In order to characterize the perturbation from baseline caused by inductive burn/tenotomy, clusters were first preliminarily generated unsupervised, and subsequently rank correlated by centroids. This allowed to consolidate clusters into seven cell families, and subsequently compare them across replicates both within a single timepoint and across all timepoints. Clusters show high intra-timepoint stability, as demonstrated by the red diagonals in rank correlation heatmaps for each timepoint and PCA plots. The only notable exception to correlation with self was cluster A that showed a reciprocal minor correlation with cluster D. Based on this high fidelity, replicates within timepoints were pooled for subsequent analysis, with proportional contribution to each cluster from all replicates confirmed by PCA plots (Supplemental Figs. [1--12](#MOESM1){ref-type="media"}). The resulting seven clusters (Fig. [2a](#Fig2){ref-type="fig"}) were identified via gene ontology terms and KEGG pathway analyses (Tables [1](#Tab1){ref-type="table"}--[7](#Tab7){ref-type="table"}) in addition to characteristic gene expression (Supplemental Figs. [13--15](#MOESM1){ref-type="media"}): mesenchymal stem cells (*Pdgfra*), satellite cells with putative stromal progenitors (*Pax7*), Schwann cells/neural progenitors (*Plp1, Cnp, Dhh*), myofibroblasts (MFB) encompassing pericytes and smooth muscle cells (*Acta2, Mylk*), endothelia/vascular progenitor cells (*Cdh5, Pecam, Cd34*), lymphocytes (*Ms4a1*), and myeloid cells including macrophages (*Ccr2, Mrc1, Fcgr1*), granulocyte (*Ccr1, S100a9*), dendritic cells (*Cd209a*). Fold change and adjusted *P* values for genes of interest are included in Table [8](#Tab8){ref-type="table"}. Notably, the endothelial/vascular progenitors cluster (D) demonstrated expression of both *Prom1(Cd133)* and *Cd34* (Fig. [2b](#Fig2){ref-type="fig"}, top/middle), corresponding to the EPC subpopulation identified in flow cytometry (Fig. [1c, d](#Fig1){ref-type="fig"}). This cluster also demonstrated high expression of mature endothelium genes (Supplemental Fig. [1](#MOESM1){ref-type="media"}) suggesting a mixed phenotype of the EPC and endothelium identified earlier in the flow cytometry. *VeCadherin*/*Cdh5* (Fig. [2b](#Fig2){ref-type="fig"}, bottom) also robustly marked this cellular subpopulation. However, this cluster did not exhibit high *Vegfa* expression levels (Fig. [2c](#Fig2){ref-type="fig"}) across any timepoints, suggesting these cells actually were not the likely source for VEGFA signal. To verify these findings, we looked to reconcile data from previous studies that have identified cells of the endothelial lineage to serve as potential HO progenitor cells using a Tie-Cre^[@CR33]^ marker. These models, however, did not use inducible systems which allow for adult labeling of cells, which is necessary to assess the true contribution of adult endothelial cells to posttraumatic HO. To address this limitation, inducible tdTomato reporter mice expressing creERT driven by the Cdh5 promoter were treated with tamoxifen with washout prior to burn/tenotomy to interrogate the spatial arrangement of early cells of endothelial lineage. Histological analysis demonstrated Cdh5+ cells spatially peripheral to the forming HO lesion but a distinct absence of Cdh5+ cells in the inflamed soft tissue deep to the cutaneous/stromal layers at 1 week (Fig. [2d](#Fig2){ref-type="fig"}, green). These cells remained a minor population in the progressing HO anlagen even at the 3 week timepoint (Fig. [2d](#Fig2){ref-type="fig"}, yellow), in stark contrast to the copious number of VEGFA-expressing cells seen in the same region (Fig. [2d](#Fig2){ref-type="fig"}, right). With the observation of Cdh5 enrichment in the periphery of pre-HO anlagen, we corroborated the significant enrichment in the surrounding stroma compared with pre-HO tissue via thresholded quantification of endogenous reporter micrographs (Fig. [2e](#Fig2){ref-type="fig"}). Thus, we verified that progenitors from endothelial lineages were not likely candidate precursors to the formation of HO, nor sources for VEGFA within the HO niche. The relatively few numbers of Cdh5+ cells within the HO analgen is consistent with previous studies showing that mesenchymal cells of nonendothelial lineage (i.e. *Prx*+, *Mx1*+, or *Scx*+) are the traumatic HO progenitors.^[@CR34],[@CR36],[@CR37],[@CR49]^ Having demonstrated that HO lesions are highly vascular but that cells of endothelial origin do not densely populate the interior of the HO anlagen, we next examined whether VEGFA expression spatially correlated with other cellular subpopulations.Fig. 2Vascular progenitors are not the source for VEGFA in HO formation. **a** Resultant seven clusters identifying cellular subpopulations within HO anlagen at respective timepoints. **b** Expression profiles for vascular progenitor genes *Prom1 (Cd133), CD34*, and *Vecad/Cdh5*. **c** Expression profile for *Vegfa* **d** Schematic for induction protocol of endogenous reporter mice. VeCadherin-creERT2/tdTomato^*fl/fl*^ identify cells with endothelial programming within outlined regions. Sections taken from distal hindlimb of injury. Right: Sections of injury site from wild-type 3 week burn/tenotomy mice labeled for VEGFA. **e** Tiled immunofluorescent micrograph of 3 week burn/tenotomy injury site in endogenous VeCadherin reporters. Quantifications for thresholded total positive area (FIJI/ImageJ) were performed across biological triplicate, with 2 hpf per specimen for both HO anlagen site vs. surrounding stroma (*n* = 6/group)Table 1Cluster A: Top 10 upregulated terms from KEGG and Gene Ontology DomainsIDNameConcept\#GenesFDRmmu04141Protein processing in endoplasmic reticulumKEGG1565.56E−10mmu00510N-Glycan biosynthesisKEGG431.79E−06mmu04512ECM-receptor interactionKEGG821.95E−05mmu03060Protein exportKEGG227.76E−05mmu04310Wnt signaling pathwayKEGG1370.000 162mmu00532Glycosaminoglycan biosynthesis - chondroitin sulfate/dermatan sulfateKEGG210.000 213 33mmu00534Glycosaminoglycan biosynthesis - heparan sulfate/heparinKEGG220.000 468 57mmu04120Ubiquitin mediated proteolysisKEGG1270.001 014 98mmu05217Basal cell carcinomaKEGG500.001 937 43mmu04350TGF-beta signaling pathwayKEGG780.005 932 52GO:0005578Proteinaceous extracellular matrixGOCC2842.14E−36GO:0031012Extracellular matrixGOCC4101.73E−27GO:0044420Extracellular matrix componentGOCC1219.66E−17GO:0005783Endoplasmic reticulumGOCC1 2341.58E−13GO:0005794Golgi apparatusGOCC1 1131.57E−12GO:0005604Basement membraneGOCC933.48E−09GO:0044432Endoplasmic reticulum partGOCC4232.29E−07GO:0005793Endoplasmic reticulum-Golgi intermediate compartmentGOCC533.12E−07GO:0005581Collagen trimerGOCC714.70E−06GO:0005801*Cis*-golgi networkGOCC324.70E−06GO:0005201Extracellular matrix structural constituentGOMF355.06E−07GO:0005539Glycosaminoglycan bindingGOMF1571.17E−06GO:0008201Heparin BindingGOMF1201.25E−06GO:0016758Transferase activity, transferring hexosyl groupsGOMF1492.51E−06GO:1901681Sulfur compound bindingGOMF1835.05E−05GO:0019838Growth factor bindingGOMF1160.000 216 25GO:0016757Transferase activity, transferring glycosyl groupsGOMF2290.000 429 31GO:0017147Wnt-protein bindingGOMF300.000 451 6GO:0004576Oligosaccharyl transferase activityGOMF570.000 524 88GO:0001968Fibronectin bindingGOMF270.000 738 19GO:0001501Skeletal system developmentGOBP4123.26E−15GO:0051216Cartilage developmentGOBP1511.10E−14GO:0061448Connective tissue developmentGOBP2054.24E−14GO:0030198Extracellular matrix organizationGOBP1891.43E−12GO:0043062Extracellular structure organizationGOBP1901.94E−12GO:0009100Glycoprotein metabolic processGOBP2658.91E−12GO:0048736Appendage developmentGOBP1602.40E−11GO:0060173Limb developmentGOBP1602.40E−11GO:0035107Appendage morphogenesisGOBP1427.77E−11GO:0035108Limb morphogenesisGOBP1427.77E−11Table 2Cluster B: Top 10 upregulated terms from KEGG and Gene Ontology DomainsIDNameConcept\#GenesFDRmmu03010RibosomeKEGG682.00E−19mmu05412Arrhythmogenic right ventricular cardiomyopathy (ARVC)KEGG710.000 437 49mmu04080Neuroactive ligand-receptor interactionKEGG1540.017 800 51mmu04740Olfactory transductionKEGG210.028 569 4mmu05410Hypertrophic cardiomyopathy (HCM)KEGG770.093 835 47mmu05414Dilated cardiomyopathyKEGG800.106 303 39mmu04020Calcium signaling pathwayKEGG1430.159 608 01mmu04260Cardiac muscle contractionKEGG590.179 346 27mmu04960Aldosterone-regulated sodium reabsorptionKEGG350.185 410 25mmu04340Hedgehog signaling pathwayKEGG450.230 030 64GO:0022626Cytosolic ribosomeGOCC801.22E−38GO:0044391Ribosomal subunitGOCC1315.61E−31GO:0022625Cytosolic large ribosomal subunitGOCC435.86E−28GO:0044445Cytosolic partGOCC1633.82E−27GO:0005840RibosomeGOCC1803.30E−26GO:0015934Large ribosomal subunitGOCC762.36E−21GO:0030016MyofibrilGOCC1677.33E−21GO:0043292Contractile fiberGOCC1808.64E−19GO:0030017SarcomereGOCC1481.09E−18GO:0044449Contractile fiber partGOCC1611.68E−18GO:0003735Structural constituent of ribosomeGOMF1513.61E−26GO:0019843rRNA bindingGOMF572.47E−14GO:0005198Structural molecule activityGOMF4321.66E−13GO:0000981RNA polymerase II transcription factor activity, sequence-specific DNA bindingGOMF5037.69E−09GO:0001071Nucleic acid binding transcription factor activityGOMF8041.48E−07GO:0003700Transcription factor activity, sequence-specific DNA bindingGOMF8041.48E−07GO:0030552cAMP bindingGOMF211.60E−07GO:0001228Transcriptional activator activity, RNA polymerase II transcription regulatory region sequence-specific bindingGOMF2637.22E−06GO:0043565Sequence-specific DNA bindingGOMF7697.64E−06GO:0030551Cyclic nucleotide bindingGOMF318.48E−06GO:0007517Muscle organ developmentGOBP3071.56E−22GO:0007519Skeletal Muscle tissue developmentGOBP1492.23E−21GO:0060538Skeletal muscle organ developmentGOBP1533.10E−21GO:0014706Striated muscle tissue developmentGOBP3291.84E−20GO:0060537Muscle tissue developmentGOBP3444.68E−20GO:0061061Muscle structure developmentGOBP5271.75E−18GO:0035914Skeletal muscle cell differentiationGOBP668.23E−18GO:0060415Muscle tissue morphogenesisGOBP661.76E−15GO:0055001Muscle cell developmentGOBP1493.30E−15GO:0006936Muscle contractionGOBP2267.59E−15Table 3Cluster C: Top 10 upregulated terms from KEGG and Gene Ontology DomainsIDNameConcept typeX.GenesFDRmmu04514Cell adhesion molecules (CAMs)KEGG1084.99E−07mmu04360Axon guidanceKEGG1237.75E−06mmu05412Arrhythmogenic right ventricular cardiomyopathy (ARVC)KEGG690.003 312 12mmu04530Tight junctionKEGG1070.005 248 1mmu04971Gastric acid secretionKEGG590.027 180 8mmu04012ErbB signaling pathwayKEGG840.040 082 96mmu04512ECM-receptor interactionKEGG810.048 468 92mmu05414Dilated cardiomyopathyKEGG780.048 468 92mmu05410Hypertrophic cardiomyopathy (HCM)KEGG740.081 685 01mmu04540Gap junctionKEGG750.081 685 01GO:0030424AxonGOCC4352.03E−23GO:0097458Neuron PartGOCC1 2238.88E−20GO:0043005Neuron projectionGOCC9634.47E−18GO:0043209Myelin sheathGOCC1957.26E−18GO:0045202SynapseGOCC6782.59E−14GO:0033267Axon partGOCC2321.12E−13GO:0044304Main axonGOCC652.20E−12GO:0036477Somatodendritic compartmentGOCC7003.91E−11GO:0044456Synapse partGOCC5103.91E−11GO:0043218Compact myelinGOCC195.42E−11GO:0005249Voltage-gated potassium channel activityGOMF552.78E−07GO:0005267Potassium channel activityGOMF802.36E−06GO:0008092Cytoskeletal protein bindingGOMF7114.23E−06GO:0015079Potassium ion transmembrane transporter activityGOMF1074.23E−06GO:0005200Structural constituent of cytoskeletonGOMF601.22E−05GO:0015267Channel activityGOMF2931.24E−05GO:0022803Passive transmembrane transporter activityGOMF2931.24E−05GO:0005251Delayed rectifier potassium channel activityGOMF234.27E−05GO:0022836Gated channel activityGOMF1990.000 110 22GO:0005216Ion Channel activityGOMF2640.000 123 54GO:0010001Glial Cell differentiationGOBP1741.23E−33GO:0007272Ensheathment of neuronsGOBP1082.31E−30GO:0008366Axon ensheathmentGOBP1082.31E−30GO:0042552MyelinationGOBP1066.00E−30GO:0042063GliogenesisGOBP2322.94E−28GO:0022008NeurogenesisGOBP1 2896.92E−23GO:0021782Glial Cell developmentGOBP754.85E−17GO:0048699Generation of neuronsGOBP1 1982.86E−16GO:0014037Schwann cell differentiationGOBP324.24E−16GO:0007422Peripheral nervous system developmentGOBP631.41E−15Table 4Cluster D: Top 10 upregulated terms from KEGG and Gene Ontology DomainsIDNameConcept typeX.GenesFDRmmu04270Vascular smooth muscle contractionKEGG916.51E−17mmu05412Arrhythmogenic right ventricular cardiomyopathy (ARVC)KEGG707.57E−11mmu04510Focal adhesionKEGG1926.84E−10mmu05414Dilated cardiomyopathyKEGG791.51E−09mmu05410Hypertrophic cardiomyopathy (HCM)KEGG752.08E−08mmu04260Cardiac muscle contractionKEGG582.13E−07mmu04020Calcium signaling pathwayKEGG1457.88E−07mmu04512ECM-receptor interactionKEGG816.03E−06mmu05012Parkinson\'s diseaseKEGG1021.53E−05mmu04970Salivary secretionKEGG570.000 526 44GO:0043292Contractile fiberGOCC1782.54E−24GO:0030016MyofibrilGOCC1656.97E−24GO:0044449Contractile fiber partGOCC1596.97E−24GO:0042383SarcolemmaGOCC1248.03E−24GO:0030018Z discGOCC891.06E−22GO:0030017SarcomereGOCC1461.29E−21GO:0031674I bandGOCC1019.96E−21GO:0032432Actin filament bundleGOCC577.27E−17GO:0030055Cell-substrate junctionGOCC3422.42E−15GO:0005924Cell-substrate adherens junctionGOCC3381.18E−14GO:0005261Cation channel activityGOMF2041.07E−07GO:0008324Cation transmembrane transporter activityGOMF4161.72E−07GO:0022890inorganic cation transmembrane transporter activityGOMF3621.83E−07GO:0003779Actin bindingGOMF3264.05E−07GO:0046873Metal ion transmembrane transporter activityGOMF2961.05E−06GO:0022836Gated channel activityGOMF2055.27E−06GO:0005216Ion Channel activityGOMF2725.35E−06GO:0030551Cyclic nucleotide bindingGOMF326.42E−06GO:0015075Ion transmembrane transporter activityGOMF5388.49E−06GO:0008092Cytoskeletal protein bindingGOMF7141.18E−05GO:0003012Muscle system processGOBP2935.28E−32GO:0006936Muscle contractionGOBP2245.28E−32GO:1903522Regulation of blood circulationGOBP1902.05E−24GO:0008015Blood circulationGOBP3471.16E−21GO:0003013Circulatory system processGOBP3511.99E−21GO:0008016Regulation of heart contractionGOBP1252.07E−21GO:0061061Muscle structure developmentGOBP5271.46E−20GO:0003008System processGOBP1 1042.91E−20GO:0044057Regulation of system processGOBP3827.31E−20GO:0006939Smooth muscle contractionGOBP882.35E−18Table 5Cluster E: Top 10 upregulated terms from KEGG and Gene Ontology DomainsIDNameConcept\#GenesFDRmmu04360Axon guidanceKEGG1221.99E−10mmu04530Tight junctionKEGG1084.12E−08mmu04670Leukocyte transendothelial migrationKEGG1003.37E−05mmu04270Vascular smooth muscle contractionKEGG910.001 949 41mmu04070Phosphatidylinositol signaling systemKEGG700.002 174 78mmu05216Thyroid cancerKEGG290.004 564 17mmu04520Adherens junctionKEGG670.005 146 28mmu04720Long-term potentiationKEGG620.011 450 77mmu05100Bacterial invasion of epithelial cellsKEGG680.012 868 56mmu04330Notch signaling pathwayKEGG460.013 308 21GO:0030054Cell JunctionGOCC1 1745.40E−17GO:0005911Cell--cell junctionGOCC5701.39E−15GO:0070161Anchoring junctionGOCC6091.84E−13GO:0005912Adherens junctionGOCC5961.94E−13GO:0005913Cell--cell adherens junctionGOCC3023.22E−11GO:0042641ActomyosinGOCC611.16E−09GO:0030027LamellipodiumGOCC1362.50E−09GO:0098590Plasma Membrane regionGOCC6985.05E−09GO:0001725Stress fiberGOCC525.68E−09GO:0032432Actin Filament bundleGOCC575.68E−09GO:0045296Cadherin bindingGOMF2815.00E−10GO:0098641Cadherin binding involved in cell-cell adhesionGOMF2625.71E−08GO:0098631Protein binding involved in cell adhesionGOMF2746.95E−08GO:0098632Protein binding involved in cell-cell adhesionGOMF2698.48E−08GO:0050839Cell Adhesion molecule bindingGOMF3954.10E−07GO:0005088Ras guanyl-nucleotide exchange factor activityGOMF1075.84E−06GO:0005112Notch bindingGOMF161.49E−05GO:0019904Protein domain specific bindingGOMF5994.60E−05GO:0005085Guanyl-nucleotide exchange factor activityGOMF1695.78E−05GO:0001071Nucleic acid binding transcription factor activityGOMF8060.000 465 87GO:0003158Endothelium developmentGOBP991.22E−20GO:0045446Endothelial cell differentiationGOBP851.06E−19GO:0001525AngiogenesisGOBP3864.52E−17GO:0001667Ameboidal-type cell migrationGOBP3061.39E−16GO:0043542Endothelial cell migrationGOBP1374.28E−16GO:0048514Blood Vessel morphogenesisGOBP4674.29E−16GO:0072358Cardiovascular system developmentGOBP5871.10E−15GO:0001944Vasculature developmentGOBP5762.60E−15GO:0001568Blood vessel developmentGOBP5523.65E−15GO:0001885Endothelial cell developmentGOBP535.44E−15Table 6Cluster F: Top 10 upregulated terms from KEGG and Gene Ontology DomainsIDNameConcept\#GenesFDRmmu03010RibosomeKEGG683.07E−25mmu05340Primary immunodeficiencyKEGG313.98E−19mmu04660T-cell receptor signaling pathwayKEGG1051.28E−16mmu05332Graft-versus-host diseaseKEGG284.22E−15mmu05320Autoimmune thyroid diseaseKEGG294.18E−14mmu05330Allograft rejectionKEGG301.33E−13mmu04650Natural killer cell mediated cytotoxicityKEGG922.20E−13mmu04940Type I diabetes mellitusKEGG333.65E−11mmu04640Hematopoietic cell lineageKEGG711.84E−10mmu04060Cytokine-cytokine receptor interactionKEGG1998.44E−10GO:0022626Cytosolic RibosomeGOCC802.70E−31GO:0009897External side of plasma membraneGOCC2281.65E−28GO:0098552Side of membraneGOCC3911.20E−27GO:0044391Ribosomal subunitGOCC1311.01E−22GO:0001772Immunological synapseGOCC322.26E−21GO:0044445Cytosolic partGOCC1631.36E−20GO:0022625Cytosolic large ribosomal subunitGOCC439.01E−20GO:0005840RibosomeGOCC1791.35E−17GO:0022627Cytosolic small ribosomal subunitGOCC301.19E−15GO:0015934Large ribosomal subunitGOCC761.88E−13GO:0003735Structural constituent of ribosomeGOMF1513.26E−19GO:0005070SH3/SH2 adapter activityGOMF233.78E−12GO:0003823Antigen bindingGOMF514.75E−12GO:0004896Cytokine receptor activityGOMF809.70E−12GO:0004872Receptor activityGOMF7723.96E−11GO:0004888Transmembrane signaling receptor activityGOMF5453.96E−11GO:0038023Signaling receptor activityGOMF6263.96E−11GO:0060089Molecular transducer activityGOMF7723.96E−11GO:0099600Transmembrane receptor activityGOMF5685.16E−11GO:0019843rRNA bindingGOMF573.40E−10GO:0046649Lymphocyte activationGOBP5385.60E−48GO:0045321Leukocyte activationGOBP6296.12E−44GO:0042110T-cell activationGOBP3811.97E−42GO:0070489T-cell aggregationGOBP3811.97E−42GO:0071593Lymphocyte aggregationGOBP3821.97E−42GO:0070486Leukocyte aggregationGOBP3885.58E−42GO:0007159Leukocyte cell-cell adhesionGOBP4141.40E−41GO:0030098Lymphocyte differentiationGOBP2949.69E−38GO:0001775Cell activationGOBP7265.47E−37GO:0030217T-cell differentiationGOBP2182.00E−36Table 7Cluster G: Top 10 upregulated terms from KEGG and Gene Ontology DomainsIDNameConcept\#GenesFDRmmu04142LysosomeKEGG1195.08E−14mmu04145PhagosomeKEGG1286.29E−13mmu05140LeishmaniasisKEGG636.29E−13mmu05150Staphylococcus aureus infectionKEGG427.05E−10mmu05323Rheumatoid arthritisKEGG746.01E−09mmu04062Chemokine signaling pathwayKEGG1641.71E−08mmu04380Osteoclast differentiationKEGG1113.92E−08mmu00190Oxidative phosphorylationKEGG1075.01E−08mmu04612Antigen processing and presentationKEGG535.60E−08mmu04620Toll-like receptor signaling pathwayKEGG866.44E−08GO:0000323Lytic VacuoleGOCC3832.20E−27GO:0005764LysosomeGOCC3832.20E−27GO:0005773VacuoleGOCC9102.20E−16GO:0098552Side of membraneGOCC3961.39E−11GO:0045335Phagocytic vesicleGOCC463.58E−11GO:0016469Proton-transporting two-sector ATPase complexGOCC351.78E−10GO:0098796Membrane protein complexGOCC8031.78E−10GO:0044437Vacuolar partGOCC3172.82E−10GO:0005774Vacuolar membraneGOCC3035.79E−10GO:0009897External side of plasma membraneGOCC2325.79E−10GO:0015078Hydrogen ion transmembrane transporter activityGOMF773.46E−09GO:0004896Cytokine receptor activityGOMF821.57E−08GO:0036442Hydrogen-exporting ATPase activityGOMF243.01E−08GO:0019829Cation-transporting ATPase activityGOMF524.24E−07GO:0035586Purinergic receptor activityGOMF216.63E−07GO:0042625ATPase coupled ion transmembrane transporter activityGOMF531.00E−06GO:0003823Antigen bindingGOMF511.14E−06GO:0016820Hydrolase activity, acting on acid anhydrides, catalyzing transmembrane movement of substancesGOMF861.21E−06GO:0015077Monovalent inorganic cation transmembrane transporter activityGOMF2412.68E−06GO:0001614Purinergic nucleotide receptor activityGOMF173.11E−06GO:0006955immune responseGOBP8751.04E−69GO:0050776Regulation of immune responseGOBP4721.26E−44GO:0006952Defense responseGOBP1 0141.28E−44GO:0002252Immune effector processGOBP5661.08E−41GO:0002250Adaptive immune responseGOBP2758.39E−40GO:0045321Leukocyte activationGOBP6302.17E−39GO:0002682Regulation of immune system processGOBP9874.64E−39GO:0045087Innate Immune responseGOBP4302.15E−37GO:0002443Leukocyte mediated immunityGOBP2421.29E−36GO:0001775Cell activationGOBP7294.04E−36Table 8Cluster identities---characteristic genesGeneFold changeAdj. *P*-valueA. Mesenchymal stem cells* Pdgfra*2.535 350 8350* Prrx1*2.107 476 6320B. Satellite cells/stromal progenitors* Pax7*2.874 586 6690C. Schwann cells/neural progenitors* Plp1*22.637 784 390* Cnp*12.449 861 550* Dhh*2.683 388 5590D. Myofibroblasts* Acta2 (aSMA)*24.233 088 110* Mylk*10.489 084 020E. Endothelial/vascular progenitor cells* Cdh5 (VeCadherin)*11.049 161 630* Pecam1*10.105 707 910* Cd34*2.496 854 6660F. Lymphocytes* Ms4a1*6.438 651 3320G. Myeloid cells* Ccr2*4.634 343 8970* Mrc1*4.064 399 0870* Fcgr1*2.972 696 050* Ccr1*2.366 385 4930* S100a9*7.099 537 9590* Cd209a*1.899 307 9181.11E−228

Mesenchymal progenitor cells, instead of endothelial lineage cells, comprise the majority of cells within traumatic HO lesions {#Sec5}
------------------------------------------------------------------------------------------------------------------------------

Unsupervised clustering yielded seven unique clusters (Fig. [2c](#Fig2){ref-type="fig"}), representing clusters of infiltrating inflammatory cells including macrophages, dendritic cells, and granulocytes, lymphocytes, endothelial cells/vascular progenitors, satellite cells with putative stromal progenitors, and progenitor subpopulations including mesenchymal stem cells, stromal progenitors, neural progenitors, and vascular progenitors. The mesenchymal stem cell population (cluster A) exhibited a remarkably constrained expression of *Pdgfra, Osr2, and En1* (Fig. [3a](#Fig3){ref-type="fig"}), all markers for a variety of progenitor populations reported in existing literature. *Vegfa* expression was indeed found in the *Pdgfra* expressing population across all timepoints (Fig. [3b](#Fig3){ref-type="fig"}). Interestingly, *Vegfa* expression was also found in macrophage populations after injury (Fig. [3c](#Fig3){ref-type="fig"}). Visualized as a timecourse, the mesenchymal stem cell cluster seems to become more heterogenous as a function of time, differentiating into a population with diluted enrichment in *Pdgfra, Prrx1*, and *Vegfa*, along with the expected expression of chondrogenic (*Sox9*) and preosteoblast (*Runx2*) markers (Fig. [3d](#Fig3){ref-type="fig"}, top). This expression profile is starkly contrasted by robust downregulation in chondrogenic and osteoblastic genes in the vascular cluster (Fig. [3d](#Fig3){ref-type="fig"}, bottom), further corroborating that these cells are not the progenitors for HO formation, nor do they produce VEGFA. Simultaneously referencing the expression profiles (Fig. [3a, b](#Fig3){ref-type="fig"}), *Vegfa* seems to correspond strongly with a subpopulation of the mesenchymal stem cell cluster strongly expressing *Pdgfra*. Immunofluorescent histology confirmed robust synthesis of VEGFA at the injury site, colocalizing with PDGFRα positive cells (Fig. [3e](#Fig3){ref-type="fig"}), with significant increases in both signals compared with contralateral control and a direct correlation between PDGFRα and VEGFA signal (Fig. [3f](#Fig3){ref-type="fig"}).Fig. 3Mesenchymal progenitor cells comprise the majority of VEGFA expressing cells within HO lesions. Clusters from 10× RNA sequencing across days 0, 3, 7, and 21 timepoints. Expression profiles corresponding to **a** mesenchymal progenitor cells: *Pdgfra, Osr2, and En1*; **b** *Vegfa*; **c** and macrophages: *Mrc1* and *Adgre1*. **d** Expression heatmap delineating timecourse for log-fold changes in expression for genes of interest within (Top) mesenchymal stem cell cluster A and (Bottom) endothelial cells/vascular progenitor cells cluster E. Red and blue signify upregulation and downregulation respectively. **e** Representative immunolabeling from burn/tenotomy on wild-type mice 1 week after injury. *n* = 3/group. Color dotted squares designate magnified regions. White dotted lines circumscribe residual bellies of Achilles tendon. Dash dot lines outline reference native bone (calcaneus). Scalebars represent 100 μm. **f** Quantifications for relative signal in 1-week injury site (left leg) vs. uninjured contralateral limb (right leg) following automated thresholding (Yen). Linear regression of PDGFRα vs. VEGFA demonstrates significant correlation

*Vegfa* is variably expressed across MSC progenitors and their differentiated progeny {#Sec6}
-------------------------------------------------------------------------------------

In order to characterize the MSC cluster with more granularity, we performed a subanalysis on the interesting MSC cluster (Fig. [4a](#Fig4){ref-type="fig"}) in light of the suggestive expression profiles pointing to differentiating/differentiated cells like chondrocytes (*Sox9*) and preosteoblasts (*Runx2*) (Fig. [3d](#Fig3){ref-type="fig"}). Transcripts profiling tenocytes (*Scx*^*+*^*Col1a1*^*+*^), MSC (*Pdgfra*^*+*^*Sox9*^*-*^*Runx2*^*-*^), chondrocytes (*Sox9*^*+*^*Acan*^*+*^*Col1a1*^*+*^*Col3a1*^*+*^), and preosteoblasts (*Runx2*^*+*^*Col1a1*^*+*^) were used to stratify subgroups within the MSC cluster 'A.' These cells were observed to peak In number at day 7, with MSCs (day 7: 1 309 MSCs vs. 269 chondrocytes, 842 preosteoblasts, and 324 tenocytes) the dominant subpopulation comprising this MSC cluster and were subsequently analyzed for their level of *Vegfa* expression as shown in resulting violin plots (Fig. [4c](#Fig4){ref-type="fig"}). *Vegfa* was found in low levels within residual tendon that was attenuated by day 7. Conversely, at day 3, MSCs along with chondrocytes, and preosteoblasts to a lesser degree were found to be enriched in *Vegfa*. This transiently dissipated for both MSCs and chondroblasts by day 7. However, more terminally differentiating cells, pre-osteoblasts were found to propagate this *Vegfa* signal even into day 21. With this sustained signaling from MSCs through more differentiated progeny, we investigated a suitable candidate driver that could simultaneously attenuate *Vegfa* expression across the predominant MSCs, but also the spectrum of their differentiation following musculoskeletal polytrauma. We observed *Prrx1* to overlap robustly with not only *Pdgfra* cells, but also *Sox9* and *Runx2* subpopulations as well (Fig. [4d](#Fig4){ref-type="fig"}). Given confirmation of transcriptional and translational expression of *Vegfa* from mesenchymal stem cells and their progeny in the injury niche, we hypothesized that conditional knockout in these cells would produce a reduction in posttraumatic HO.Fig. 4*Vegfa* is variably expressed amongst MSC progenitors and their differentiated progeny. **a** Schematic of cluster subanalysis of MSC cells from single-cell RNA sequencing. **b** Discrete counts of cell types and classification criteria. **c** Expression levels of *Vegfa* across all indicated cell types. **d** Expression profiles of characteristic markers *Prrx1*; mesenchymal progenitors: *Pdgfra;* chondrocytes: *Sox9;* and preosteoblasts: *Runx2*

Conditional genetic deletion of VEGFA from Prx1 lineage cells decreases posttraumatic extremity HO {#Sec7}
--------------------------------------------------------------------------------------------------

Having identified an increase in vascularity at a traumatic HO site and characterized a potential source for vascular signal, we next set out to assess the role of *Prx1*+ lineage cell derived VEGFA. Our single-cell RNA sequencing data reaffirm co-expression of *Pdgfra* and *Prrx1* (Fig. [4d](#Fig4){ref-type="fig"}), corroborating our previously demonstrated work showing cells of the *Prx1*+ lineage define the HO progenitor cells.^[@CR34]^ In addition, VEGFA has been shown to be produced by osteoprogenitor cells and to drive bone development.^[@CR50]^ Recent studies also demonstrate that VEGFA from cells marked by Col2CreER-mediated recombination, but not vascular cell lineage (Flt1) functions as a survival and differentiation factor for chondrocytes.^[@CR51]^ Thus, to evaluate the role of VEGFA on ectopic cartilage formation, we deleted VEGFA from cells of the *Prx1+* lineage. Following VEGF deletion from *Prx1+* MSCs via *Prx1*-cre/*Vegf*^*fl/fl*^, these mutant mice produced significantly less HO in the distal hindlimb (44% relative reduction, *P* = 0.036 after normalization by cortical thickness due to stunted limb phenotype) when induced by burn/tenotomy (Fig. [5a](#Fig5){ref-type="fig"}). Given the density of PDGFRα^+^ cells observed with histology, the reduction in ectopic bone formation following selective gene knockout, implicates VEGFA expression and production by MSCs as a major niche in the acute inflammatory response after burn/tenotomy. Additional histological analyses of injury sites of *Prx1*-cre/*Vegf*^*fl/fl*^ 9 weeks post injury exhibit a profound absence i.e. significant ablation of VEGFA signaling in the deletion mice compared with littermate controls, despite comparable levels of PDGFRα^+^ cells (Supplemental Fig. [2](#MOESM1){ref-type="media"}) validating the degree of gene ablation.Fig. 5VEGFA knockout and molecular inhibition attenuates formation of HO in the distal hindlimb. Following 9 weeks burn tenotomy, **a** *Prx*-Cre;*Vegf*^*fl/fl*^; treated WT mice exhibit lower volumes of heterotopic ossification than their corresponding controls at 800 HU. Prx-Cre HO volumes normalized by mean cortical thickness (mm) due to congenital phenotype. *n* = 4--9/group. Bars represent means and SD. \**P* \< 0.05 vs. Control by Student's *t* test. **b** Magnified images of human HO samples immunolabeled for VEGFA: (1,2) pre-HO stroma, (3,4) early HO formation with surrounding stromal fibroblasts, (5,6) intermediate HO, and (7,8) mature HO with terminal ossification. VEGFA indicated by red, scalebar indicates 100 μm

Finally, histology was obtained from human HO specimens with diverse morphologies that reflect the full histologic spectrum of human disease (Fig. [5b](#Fig5){ref-type="fig"}, *n* = 10 human specimens). VEGFA immunostaining was performed, which paralleled our findings from mouse tissues. In early spindle cell lesions before frank ossification (Fig. [5b1,2](#Fig5){ref-type="fig"}), a high density of VEGF immunoreactive cells were present. In other areas with early and inconscipuous amounts of woven bone, noticeably stronger VEGF immunoreactivity was present within bone-lining cells (Fig. [5b3,4](#Fig5){ref-type="fig"}). These findings were consistent across specimens and in areas of more conspicuous lamellar bone (Fig. [5b5,6](#Fig5){ref-type="fig"}), in which bone-lining cells were the again prominently VEGF immunoreactive. In samples with HO of a thicker, more 'cortical' appearance (Fig. [5b7,8](#Fig5){ref-type="fig"}) bone-lining cells continued to show VEGF immunoreactivity while osteocytes within thicker bone fragments showed little staining. Thus, and across human samples, VEGF highlights similar populations of HO stromal progenitor cells and osteoblasts as in our mouse models, suggesting a potentially similar pathophysiology and disease course.

Discussion {#Sec8}
==========

HO is the formation of ectopic bone highly reliant on angiogenesis to progress through endochondral ossification to mature into its mineralized, final form. VEGFA is regulated by many transcription factors including HIF1a which is thought to be a major stimulus in cancer, bone development, and bone pathology.^[@CR19],[@CR34],[@CR50],[@CR52]^ Having identified the central role of HIF1a in traumatic HO, we set out to determine whether VEGFA, a downstream signaling mediator of HIF1a, is involved in HO formation.

Previous studies have shown that VEGFA orchestrates ossification during normal bone development.^[@CR53]^ Furthermore, elegant studies have demonstrated that VEGFA produced by cells of Osx-Cre lineage regulate blood vessel recruitment and early osteoblast differentiation^[@CR21]^ and that VEGFA produced by *Col2*-Cre-marked cells is necessary for chondrocyte survival.^[@CR51]^ We chose to target VEGFA in cells of the Prx1-Cre lineage as we were the first to identify these cells as the HO progenitor cells,^[@CR34]^ a decision further supported by our transcriptomic and histologic data correlating *Prrx1* and *Pdgfra* expression. Notably, in our model, chondrocytes provided limited contribution to *Vegfa* expression levels. However, preosteoblasts were found to be the responsible cell population for *Vegfa* expression at later timepoints (D21), demonstrating that in addition to recruited MSCs, their differentiating progeny propagated the robust expression *Vegfa*. While MSCs were the dominant source for *Vegfa* expression both in magnitude and volume (Fig. [4](#Fig4){ref-type="fig"}), the heterogeneity of *Vegfa* also deriving from chondroblasts and preosteoblasts further reinforced our strategy in producing VEGFA knockout via a Prx1 driver. Of particular note from a bioinformatics perspective, while the overwhelming majority of clusters demonstrated high specificity in alignment, two clusters A and D showed moderate levels of correspondence to each other following the initial pseudo clustering (Fig. [2a](#Fig2){ref-type="fig"}). These clusters correspond to related progenitor cells, both expressing a common ancestry given their prrx1 enrichment. However, the musculoskeletal mesenchymal progenitor population (D) exhibited sparse VEGFA signaling, essentially rendering this an inert subpopulation. Here we show that genetic loss of VEGFA from the mesenchymal stem cell population (along with some chondrocyte and preosteoblasts) is sufficient to significantly reduce HO volume. VEGFA inhibition in cells of the Prx-Cre lineage did not, however, completely mitigate all HO formation likely due to alternative sources for VEGFA as demonstrated in our single-cell RNA sequencing, namely inflammatory cells.^[@CR51],[@CR54],[@CR55]^ Despite previous literature implicating vascular sources of VEGFA secreted in a cell autonomous manner,^[@CR48]^ our sequencing data concretely demonstrated a notable absence of *Vegfa* transcripts. In addition, these cells did not express common markers of chondrogenic and osteoblastic differentiation, cementing their supportive role in the periphery of the developing ectopic bone.

Histological analysis of our acute injury model demonstrated a lack of spatial proximity between *Cdh5*-creERT2 cells and VEGFA within the HO region when activated just prior to injury. Cells positive for *Cdh5*, however, were present in a large amount surrounding the mesenchymal condensation that underwent endochondral ossification corroborating our sequencing results and the *Cdh5*+ cell's important supportive role to the HO niche. This presence of *Cdh5+* cells also corresponded with an increase in blood flow as well as blood vessels likely derived from the identified EPCs, which is consistent with the rubor and swelling seen at a joint predisposed to HO prior to radiographic evidence.

Two pathways could explain our observed phenotype of HO inhibition following loss of mesenchymal-derived VEGFA: decreased angiogenesis secondary to loss of the trophic signal leading to an indirect deleterious effect on endochondral ossification or direct phenotypic changes to the mesenchymal cells themselves. Interestingly, our mesenchymal stem cell population did not exhibit upregulation of any VEGF receptors, including *Flt1*/VEGFR1, *Kdr*/VEGFR2, or *Flt4*/VEGFR3 (data not shown) rendering them unresponsive to VEGFA. This is largely concordant with previous literature characterizing VEGFA activity in fetal tissues.^[@CR23]^ Given the large influx of inflammatory cells including VEGFA expressing macrophages, one could presume that there should be enough residual VEGFA at the locus of injury to rescue the loss of mesenchymal-derived VEGFA, especially with the former pathway. Given our observed reduction in HO, it seems the latter pathway is more likely. Indeed, previous work by Zelzer et al. ^[@CR23]^ demonstrated that VEGFA loss from mesenchymal stem cells leads to aberrant growth plate development despite no changes to surrounding vasculature, instead pointing to transcriptional changes within the differentiated mesenchymal cells and chondroblasts themselves. Furthermore, in this paradigm, the partial bone phenotype is unsurprising as *Pdgfra/Prrx1* cells highly expressing VEGFA were a subpopulation of a larger pool of progenitors. Nevertheless, the targeted ablation of VEGFA was observed to produce marked, clinically-relevant reductions of posttraumatic HO. As such, future work could involve utilization of selective, deliverable next-generational inhibitors such as siRNAs for cell-specific knockdowns to attenuate HO formation.

This work is also the first to our knowledge to further characterize the role for novel progenitor-cell populations rapidly expanding in the literature. Subpopulations characterized as dermal lineage progenitors like engrailed1 (*En1*)^[@CR56]^ and fibro-adipogenic progenitors like odd-skipped related-1/2 (*Osr1/2*)^[@CR57]^ were found in the larger *Pdgfra* cluster, implicating *En1* and *Osr1/2* expressing cells as subsets of a larger progenitor population involved with HO formation. These cells appear transcriptionally distinct from *Vegfa* expressing progenitors, suggesting next steps that will be necessary to further characterize the differentiation capacity of these cells in the HO niche and to what degree they differ in the disease course. In addition, given previous work demonstrating the spatial variation of different lineages i.e. concentration of Prx-positive cells in the distal hindlimb, these separate cells with progenitor phenotypes may perhaps mark more proximal contributing cells to HO formation. Downstream high-throughput analyses facilitated by Next-Gen sequencing modalities as performed in this work will offer additional insights into important phenotypes and candidate targets.

This study has several notable limitations. Our RNA-sequencing results did not offer substantial resolution between mature endothelium (Supplemental Fig. [1](#MOESM1){ref-type="media"}) and EPCs. However, the flow cytometry did mark this separation well. Furthermore, this data would suggest that analysis of VeCadherin endogenous reporters would be likely indicating both mature endothelium in addition to the EPCs on histology. Thus, a complete absence of signal necessarily still validates an absence of EPCs. We chose to use *Prx*-Cre which will mark all cells from embryonic and postnatal development rather than an inducible Cre given our previous studies that demonstrate their central role in HO using this model.^[@CR34]^ In addition, we do not delineate whether VEGF stimulates MSC differentiation^[@CR58]^ or just promotes chondrocyte survival. In addition, because of our approach to characterize perturbations of cellular populations found at baseline, these constraints limited are ability to characterize the cell populations with further granularity i.e. myeloid cells vs. individual clusters for macrophages, granulocytes, and dendritic cells. This leaves us potentially susceptible to artifacts in results specifically due to dilution of clusters (as seen in the *Vegfa* expression patterns in the mesenchymal stem cells.

Notwithstanding these limitations, our findings demonstrate that mesenchymal-derived VEGFA is a crucially expressed signal in the genesis of HO, suggesting that therapies targeting VEGFA may present a reasonable option for reducing this debilitating disease and expanding the repertoire for its prevention. Subsequent studies are required to determine the efficacy and safety profile of targeted siRNA delivery systems and existing systemic anti-VEGFA antibodies such as bevacizumab in more directed wound healing models for HO patients.

Materials and methods {#Sec9}
=====================

Ethics statement {#Sec10}
----------------

All animal experiments described were approved by the University Committee on Use and Care of Animals at the University of Michigan, Ann Arbor (Protocols: \#05909 and 07930). This study was carried out in strict accordance with the recommendations in the *Guide for the Care and Use of Laboratory Animals of the National Institutes of Health*.^[@CR59]^ All animal procedures were carried out in accordance with the guidelines provided in the *Guide for the Use and Care of Laboratory Animals: Eighth Edition* from the Institute for Laboratory Animal Research.^[@CR60]^

Animals {#Sec11}
-------

Mice evaluated for ectopic bone were wild-type C57BL/6J (Jackson Laboratories), Cdh5-Cre/tdTomato^fl/fl^ ^[@CR61]^, *VeCadherin(Cdh5)-creERT2/tdTomato*^*fl/fl*^ ^[@CR62]^ (a gift from Dr Luisa Iruela Arispe, UCLA), *Prx1-cre*^[@CR34]^*/Vegfa*^*fl/fl*^, or *Prx1-cre/Vegfa*^*fl/fl*^ littermate controls. All breeding was performed at the University of Michigan in facilities managed by the Unit for Laboratory Animal Medicine. CreERT reporters were induced with two doses of 1 mg tamoxifen in mice one week prior to burn/tenotomy for adequate washout by the time of injury.

Injury models {#Sec12}
-------------

All mice received presurgical analgesia consisting of 0.06 mg·kg^−1^ buprenorphine for 48 h, followed by anesthesia with inhaled isoflurane, and close postoperative monitoring with analgesic administration.

Mice received 30% total body surface area partial-thickness burn on a shaved dorsum followed by transection of the left Achilles tendon. Dorsal burn was induced using a metal block heated to 60 °C in a water bath and applied to the dorsum for 18 s continuously. HO anlagen was observed by week 3 with mature bone formation visible by microCT by 9 weeks.

In vivo imaging system {#Sec13}
----------------------

Mice were anesthetized via inhaled isoflurane and depilated with Nair. Specimens were imaged before injection for baseline fluorescence levels at 770-nm wavelength using an IVIS Spectrum system (PerkinElmer 124262). Per manufacturer's instructions, 100 μL of 20 μmol·L^−1^ AngioSense 750EX (PerkinElmer NEV10011EX) solution was injected into the tail vein followed by re-imaging 24 h post injection at excitation/emission of 750/800 nm. AngioSense protocol was performed 20 h post burn/tenotomy (*n* = 3/group).

10× Single-cell RNA sequencing {#Sec14}
------------------------------

Baseline uninjured tendon (day 0) and post surgery day 3, 7, and 21 harvested tissue samples were digested for 45 min in 0.3% Type 1 Collagenase and 0.4% Dispase II (Gibco) in Roswell Park Memorial Institute (RPMI) medium at 37 °C under constant agitation at 120 r·min^−1^. Digestions were subsequently quenched with 10% FBS RPMI and filtered through 40 μm sterile strainers. Cells were then washed in PBS with 0.04% BSA, counted and resuspended at a concentration of \~1 000 cells per μL. Cell viability was assessed with Trypan blue exclusion on a Countess II (Thermo Fisher Scientific) automated counter and only samples with \>85% viability were processed for further sequencing.

Single-cell 3′ library generation was performed on the 10× Genomics Chromium Controller following the manufacturer's protocol for the v2 reagent kit (10× Genomics, Pleasanton, CA, USA). Following generation of single-cell gel bead-in-emulsions (GEMs), reverse transcription was performed and the resulting Post GEM-RT product was cleaned up using DynaBeads MyOne Silane beads (ThermoFisher Scientific, Waltham, MA, USA). The cDNA was amplified, SPRIselect (Beckman Coulter, Brea, CA, USA) cleaned and quantified then enzymatically fragmented and size selected using SPRIselect beads to optimize the cDNA amplicon size prior to library construction. An additional round of double-sided SPRI bead cleanup is performed after end repair and A-tailing. Another single-sided cleanup is done after adapter ligation. Indexes were added during PCR amplification and a final double-sided SPRI cleanup was performed. Libraries were quantified by Kapa qPCR for Illumina Adapters (Roche) and size was determined by Agilent tapestation D1000 tapes. Read 1 primer sequence are added to the molecules during GEM incubation. P5, P7 and sample index and read 2 primer sequence are added during library construction via end repair, A-tailing, adapter ligation and PCR. Libraries were generated with unique sample indices for each sample. Libraries were sequenced on a HiSeq 4000, (Illumina, San Diego, CA, USA) using a HiSeq 4000 PE Cluster Kit (PN PE-410-1001) with HiSeq 4000 SBS Kit (100 cycles, PN FC-410-1002) reagents, loaded at 200 pmol·L^−1^ following Illumina's denaturing and dilution recommendations. The run configuration was 26 × 8 × 98 cycles for Read 1, Index, and Read 2, respectively. Cell Ranger Single Cell Software Suite 1.3 was used to perform sample de-multiplexing, barcode processing, and single-cell gene counting (Alignment, Barcoding and UMI Count) at the University of Michigan Biomedical Core Facilities DNA Sequencing Core.

A total of \~200-500 million reads were generated from the 10× Genomics sequencing analysis for each replicate. The sequencing data were first preprocessed using the 10× Genomics software Cell Ranger (10× Genomics Inc., Pleasanton, CA, USA) and aligned to mm10 genome (deposited to the Gene Expression Omnibus database: GSE126060). Downstream analysis steps were performed using Seurat. Cells with fewer than 500 genes, more than 10% of reads mapping to the mitochondrial genome, or more than 60 000 UMIs; and genes expressed in fewer than 10 cells per replicate, were filtered for quality control. The downstream analysis steps for each sample type include normalization, scaling, dimensionality reduction (PCA, t-SNE, and UMAP), unsupervised clustering, and the discovery of differentially expressed cell-type specific markers. We verified the absence of the within-time-point batch effect by visual inspection of the per-sample contribution in the per-day merged set, once we pooled together samples from each timepoint (Fig. [2b](#Fig2){ref-type="fig"}). In order to characterize the induced changes in cellular populations following burn/tenotomy injury, provisional clusters were identified unsupervised clustering followed by centroid rank correlation comparison within and between timepoints (days 0, 3, 7, and 21). Provisional clusters that failed to align across these comparisons were discarded, leaving behind cells and clusters that were identified in the steady state (day 0) timepoint and subsequently perturbed across days 3, 7, and 21. Final clusters were refined by pooling cells from all the timepoints to create a merged set; correcting for batch effect of the merged set; and performing a supplemental unsupervised clustering. Expression profiles of known markers, GO term and KEGG pathway analysis, along with characteristic expression profiles were utilized to identify the cell types of each cluster. FDR adjustments were performed to determine statistical significance of gene expression fold changes within a cluster vs. all other clusters within the merged set. Enrichment was performed with LRPath. The whole Bioinformatics analysis summarized here is detailed in the supplementary material (Figs. [S3](#MOESM1){ref-type="media"}--[15](#MOESM1){ref-type="media"}).

Histology and immunofluorescence {#Sec15}
--------------------------------

Histologic evaluation was performed at indicated timepoints in wild-type C57BL/6J and tdTomato endogenous reporter mutants following burn/tenotomy. TdTomato and wild-type hindlimbs were fixed at 4 °C in 4% paraformaldehyde or 10% neutral-buffered formalin. Specimens were subsequently decalcified in 14% (m/v) EDTA solution for 4--6 weeks at 4 °C until deformable manually. Hindlimbs were cryo- or paraffin-embedded and 8 μm--10 μm sections were cut and mounted on Superfrost plus slides (Fisher) and stored at −20 °C.

Paraffin sections were consistently selected from similar regions defined by talus as the anatomical landmark, rehydrated, processed for antigen retrieval in citrate buffer for 20 min at 95 °C--100 °C and blocked with 2% serum, 1% BSA, and 0.1% fish skin gelatin. Human sections were separately treated with trypsin enzymatic antigen retrieval solution (Abcam) for 10 min at 37 °C and blocked with 3% hydrogen peroxide (20 min, RT) and 5% goat serum (1 h, RT). Immunostaining of HO anlagen was performed on paraffin sections with the following antibodies: goat anti-mPDGFR-alpha (R&D Systems, AF1062) and rabbit anti-mouse VEGFA (EMD Millipore, ABS82). Secondary antibodies consisted of donkey anti-rabbit or anti-goat Alexafluor-488 or −594 (Invitrogen). Primary and fluorophore conjugated secondary antibodies were diluted 1:50--100 (2--4 μg·mL^−1^) and 1:200, respectively. Nuclear counterstain was performed with Hoechst 33342 (Life Technologies). Immunostaining of human HO was performed on paraffin sections with polyclonal rabbit anti-mouse VEGFA (Santa Cruz, Cat No. sc-152). Slides were subsequently blocked with BLOXALL solution (Vector) and 2.5% normal horse serum, and incubated with second primary antibody, IMPRESS-AP reagent (Vector) with development and counterstain via Alkaline Phosphatase Substrate and hematoxylin (Vector). Appropriate primary antibody negative controls were run simultaneously with each tested sample.

Microscopy {#Sec16}
----------

Cryosections of tdTomato endogenous reporter mice were imaged with a Zeiss LSM 510-META Laser Scanning Confocal Microscope equipped with a helium neon 1 laser (AF594, RFP). Cryosections for immunolabeled samples were performed on a Leica TCS SP8 Laser Scanning Confocal Microscope with tunable laser whose excitation and emission parameters were set to fluorophore manufacturer's instructions. Antibody labeled paraffin sections were imaged with epifluorescent upright scope (Olympus BX-51) equipped with DAPI and dual-cube 488 nm/TRITC filters attached to an Olympus DP-70 high-resolution digital camera. Each site was imaged in all channels and were overlaid in Olympus DPViewer or Photoshop before examination and quantifications in ImageJ. Images were adjusted linearly only in brightness and contrast identically across comparison groups for clarity where necessary.

For quantification of positively fluorescence, images were automatically thresholded via Yen method, and then measured across 1--3 separate hpf per biologic specimen (ImageJ, *n* = 1--3/specimen, *N* = 3 specimens/treatment group). Images were then analyzed for area via the standard ImageJ measurement panel.

Flow cytometry {#Sec17}
--------------

FACS analysis was performed on the injury site after harvesting the soft tissue of the posterior compartment between the muscular attachment of the Achilles tendon and the calcaneal insertion. Correlating soft tissue was also harvested from the contralateral uninjured leg. Tissue was digested for 60 min in 0.3% Type I Collagenase and 0.4% Dispase II (Gibco) in RPMI at 37 °C under constant agitation. Digestions were quenched with RPMI supplemented with 10% FBS and filtered using a 70-μm sterile strainer, transferred to 15 mL conical tubes, and centrifuged at 300 × *g* for 5 min. Tubes were decanted and washed in PBS three times. Digested specimens were blocked for Fc receptors with anti-mouse CD16/32 for 15 min at 4 °C, and subsequently stained with the following antibodies: Tie2-PE (12-5987-83, eBioscience), CD31-APC (551262, BD Pharmingen), CD133-AF488 (11--1331--82, eBioscience), and CD34-eFluor450 (48--0341--82, eBioscience). Following 30 min of incubation at 4 °C, samples were washed, filtered through a 35 μm mesh strainer, incubated with propidium iodide, and run on a FACSAria II (BD Biosciences) Cell Sorter at the University of Michigan Flow Cytometry Core in the Biomedical Science Research Center. For sorting, after appropriate FSC/SSC, singlets, and viable cells were gated, the CD31 and Tie2 double-negative subpopulation was enriched for CD34 positive EPCs. Tie2 and CD31 double positive subpopulations were further refined for CD133 and CD34 double-negative mature endothelium. Event counts were normalized to total viable cells to control for possible differences in the amount of tissue harvested. Data were then analyzed using FlowJo software.

MICROFIL imaging {#Sec18}
----------------

In vivo collateral vessel formation was assessed using MICROFIL. At 9 weeks after burn/tenotomy, wild-type mice were euthanized with cannulation of descending thoracic aorta and venting of inferior vena cava. Mice were perfused with MICROFIL (MV120-blue; Flow Tech Inc.) which was allowed to polymerize overnight at 4 °C and subsequently imaged with μCT (*n* = 2/group).

MicroCT analysis {#Sec19}
----------------

Mouse hind limbs were imaged with μCT at 9 weeks post injury (Bruker, 35 μm resolution and 357 μA/70 kV beam). Images were reconstructed and ectopic bone volume formation calculated with Microview (GE Healthcare v2.2, Parallax rc16). All scans were analyzed with threshold Hounsfield units (HU) of 800, 1 250, or 1 800 to determine the gross volume of mineralized tissues. Additional analyses delineated ectopic bone proximal to the tibial-fibular confluence from bone distal to this landmark and were defined as proximal and distal HO respectively.

Statistical analysis {#Sec20}
--------------------

Primary outcome of interest for *a priori* power analysis is volume of mature ectopic bone formation. To detect 50% decrease from 7.5 mm^3^ in untreated mice at significance level of 0.05 and power of 0.80, three mice were required per group. Means and SD were calculated from numerical data, as presented in text, figures, and figure legends. Bar graphs represent means with error bars specifying one SD. Sample groups were confirmed to be homoscedastic via Levene's test. Pairwise comparisons were conducted with Student's *t* test after confirmation for homoscedasticity via *F*-test. *P* values are included in figure legends.
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